Allylescaline

Allylescaline
Clinical data
Other names	AL; Allylmescaline; 4-Allyloxy-3,5-dimethoxyphenethylamine; 3,5-Dimethoxy-4-allyloxyphenethylamine
Routes of; administration	Oral
Drug class	Serotonin 5-HT2 receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code	None;
Pharmacokinetic data
Onset of action	10–50 minutes
Duration of action	8–12 hours
Identifiers
	IUPAC name {3,5-dimethoxy-4-[(prop-2-en-1-yl)oxy]phenyl}ethan-1-amine;
CAS Number	39201-75-7 ;
PubChem CID	44719469;
ChemSpider	21106254 ;
UNII	J39IWS08EN;
ChEMBL	ChEMBL126803 ;
CompTox Dashboard (EPA)	DTXSID80660348 ;
Chemical and physical data
Formula	C13H19NO3
Molar mass	237.299 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1cc(cc(OC)c1OCC=C)CCN;
	InChI InChI=1S/C13H19NO3/c1-4-7-17-13-11(15-2)8-10(5-6-14)9-12(13)16-3/h4,8-9H,1,5-7,14H2,2-3H3 ; Key:JNUAYHHGCXYBHX-UHFFFAOYSA-N ;
	(verify)

Allylescaline (AL), or allylmescaline, also known as 4-allyloxy-3,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline. It is taken orally.

The drug acts as an agonist of the serotonin 5-HT₂ receptors, including the serotonin 5-HT_2A receptor. It is closely related to other scalines including mescaline, escaline, and proscaline, among others.

Allylescaline was first described in the scientific literature by Otakar Leminger in 1972. Subsequently, it was further described by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved). It was encountered as a novel designer drug in 2013.